Navigation Links
A new radiation therapy treatment developed for head and neck cancer patients
Date:8/17/2007

lowing sparing of the adjacent normal tissues from the highest doses of radiation. Boron-mediated targeting of radiation allows treatment of patients who can no longer be treated with conventional radiation therapy. BNCT is administered as single one-day treatment that may be repeated.

The study was sponsored by Boneca Corporation, the spinoff company operating on the medical campus of the Helsinki University and the University Central Hospital (www.boneca.fi). The treatments are carried out in collaboration with the Department of Oncology, Helsinki University Central Hospital, at the BNCT facility constructed at the VTT research nuclear reactor site located at Otaniemi, Espoo. The neutron radiation used in the treatment is provided by VTT.

Boneca Corporations clinical research program includes also a phase I/II study that evaluates BNCT in the treatment of primary glioblastoma (a highly malignant brain tumour) and another clinical trial that assesses safety and efficacy of BNCT in the treatment of glioblastomas and anaplastic astrocytomas (a type of brain tumour) that have recurred after conventional radiation therapy.

Our plan is to investigate BNCT in the treatment of cancers located elsewhere in the body that cannot be effectively managed by any known treatment, says professor Heikki Joensuu.

The current treatment is a result of a long period of research, a proof of academic expertise, and a model for effective collaboration between Helsinki University Central Hospital, University of Helsinki, VTT Technical Research Centre of Finland, and the company, says Boneca Corporations managing director Markku Pohjola.


'/>"/>

Contact: Professor Heikki Joensuu
heikki.joensuu@hus.fi
358-947-173-208
University of Helsinki
Source:Eurekalert

2

GOOD

Page: 1 2

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Gene therapy may protect normal tissues during radiation retreatment for lung cancer
4. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
5. Radiation-killed bacteria vaccine induces broad immune response in mice
6. Radiation-armed robot rapidly destroys human lung tumors
7. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
8. Gene therapy protects mice from the effects of whole-body irradiation
9. Cancer stem cells linked to radiation resistance
10. Mars mission Risk 29: Scientists research ways to reduce radiation-induced brain damage
11. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):ADA releases updated position paper on nutrient supplementation 2UAB bone center director wins distinguished service award from clinical pathology society 2MSU researcher unveils new approach to treat lower back pain 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 1Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 1Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 12Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference 6021 1